FT3/FT4 ratio predict survival in surgically treated patients with renal cell carcinoma

Abstract

Aim. The primary objective of this study was to exa-mine the connection between hormone levels, speci-fically the fT3/fT4 ratio, and surgical outcomes in renal cell carcinoma patients. The study aimed to assess the prognostic value of hormone status in predicting progression-free survival and overall survival follo-wing surgery. Methods. This prospective study included patients scheduled for surgical treatment of renal cell carcino-ma. Patients aged over 18 years with ASA status I-III were enrolled in the study. Thyroid status was eva-luated by pre- and post-surgery hormone values and ultrasonography findings preoperatively. The fT3/fT4 ratio was calculated for every patient. Results. Analysis was conducted on 40 patients with complete data. The median age of the cohort was 64.3 years, with 1/4 of patients aged over 70. Clear cell carcinoma predominated (92.5%), with 55.1% falling into the intermediate international metastatic renal cell carcinoma database consortium, risk group. Surgery. In 82.5% of patients laparoscopic intervention was performed. The fT3/fT4 ratio significantly correlated with the median progression free survival (5, 14, and 20 months for low, intermediate, and high ratio groups, respectively) and median overall survival (7, 26, and 40 months for low, intermediate, and high ratio groups, respectively) (p<0.005). Conclusion. Our findings underscore the importance of the fT3/fT4 ratio as a valuable prognostic indicator for renal cell carcinoma patients undergoing surgery. The fT3/fT4 ratio was related to worse progression free survival and overall survival, emphasizing the po- potential role of hormone status in predicting out-comes. potential role of hormone status in predicting outcomes.